title: Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome.
abstract: A subunit vaccine, RBD-S, is under development to prevent severe acute respiratory syndrome (SARS) caused by SARS coronavirus (SARS-CoV), which is classified by the US NIH as a category C pathogen. This vaccine is comprised of a recombinant receptor-binding domain (RBD) of the SARS-CoV spike (S) protein and formulated on alum, together with a synthetic glucopyranosyl lipid A. The vaccine would induce neutralizing antibodies without causing Th2-type immunopathology. Vaccine development is being led by the nonprofit product development partnership; Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development in collaboration with two academic partners (the New York Blood Center and University of Texas Medical Branch); an industrial partner (Immune Design Corporation); and Walter Reed Army Institute of Research. A roadmap for the product development of the RBD-S SARS vaccine is outlined with a goal to manufacture the vaccine for clinical testing within the next 5 years.
authors.affiliation: Lindsley F Kimball Research Institute, New York Blood Center, New York, NY, USA.
authors.forename: Shibo
authors.initials: S
authors.lastname: Jiang
authors.forename: Maria Elena
authors.initials: ME
authors.lastname: Bottazzi
authors.forename: Lanying
authors.initials: L
authors.lastname: Du
authors.forename: Sara
authors.initials: S
authors.lastname: Lustigman
authors.forename: Chien-Te Kent
authors.initials: CT
authors.lastname: Tseng
authors.forename: Elena
authors.initials: E
authors.lastname: Curti
authors.forename: Kathryn
authors.initials: K
authors.lastname: Jones
authors.forename: Bin
authors.initials: B
authors.lastname: Zhan
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Hotez
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D017607:Aluminum Compounds / Q000008:administration & dosage; D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology; D000914:Antibodies, Viral / Q000276:immunology; D000956:Antigens, Viral / Q000276:immunology*; D002986:Clinical Trials as Topic; D006801:Humans; D008050:Lipid A / Q000008:administration & dosage; D008562:Membrane Glycoproteins / Q000276:immunology*; D010710:Phosphates / Q000008:administration & dosage; D017434:Protein Structure, Tertiary; D045473:Severe acute respiratory syndrome-related coronavirus / Q000276:immunology* / Q000472:pathogenicity; D045169:Severe Acute Respiratory Syndrome / Q000276:immunology / Q000517:prevention & control*; D064370:Spike Glycoprotein, Coronavirus; D022223:Vaccines, Subunit / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology; D014759:Viral Envelope Proteins / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D017607:Aluminum Compounds; D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D000956:Antigens, Viral; D008050:Lipid A; D008562:Membrane Glycoproteins; D010710:Phosphates; D064370:Spike Glycoprotein, Coronavirus; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C578557:spike glycoprotein, SARS-CoV; C578553:spike protein, mouse hepatitis virus; C012714:aluminum phosphate